Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Shares Outstanding (2019 - 2025)

BridgeBio Pharma's Shares Outstanding history spans 7 years, with the latest figure at $191.2 million for Q2 2025.

  • For Q2 2025, Shares Outstanding rose 1.66% year-over-year to $191.2 million; the TTM value through Jun 2025 reached $191.2 million, up 1.66%, while the annual FY2024 figure was $6.2 million, 96.46% down from the prior year.
  • Shares Outstanding for Q2 2025 was $191.2 million at BridgeBio Pharma, up from $189.8 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $191.2 million in Q2 2025 and bottomed at $3.2 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $160.9 million (2023), against an average of $126.9 million.
  • The largest YoY upside for Shares Outstanding was 5991.4% in 2021 against a maximum downside of 97.38% in 2021.
  • A 5-year view of Shares Outstanding shows it stood at $6.2 million in 2021, then changed by 0.0% to $6.2 million in 2022, then surged by 2727.68% to $175.1 million in 2023, then grew by 8.55% to $190.0 million in 2024, then grew by 0.59% to $191.2 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Shares Outstanding are $191.2 million (Q2 2025), $189.8 million (Q1 2025), and $190.0 million (Q4 2024).